Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration - PubMed
3 hours ago
- #Cannabinoids
- #Microglia
- #Neuroinflammation
- Non-psychotropic cannabinoids from Cannabis sativa, like cannabidiol (CBD), show promise in modulating neuroinflammation by targeting microglia, the brain's immune cells.
- These cannabinoids interact with multiple receptors and signaling pathways in microglia, offering therapeutic potential for neurodegenerative diseases such as Alzheimer's, Parkinson's, multiple sclerosis, and Huntington's disease.
- Significant gaps exist in understanding the mechanisms of cannabinoids beyond CBD, highlighting the need for further research in disease-relevant models to advance therapeutic development.
- Collaboration between cannabis breeders/cultivators and scientists is essential to bridge knowledge gaps and enhance the therapeutic evaluation of these compounds.